<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4288743</article-id><article-id pub-id-type="publisher-id">2051-1426-2-S3-P78</article-id><article-id pub-id-type="doi">10.1186/2051-1426-2-S3-P78</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin<sup>&#x000ae; </sup>(HD IL-2) and Ipilimumab Yervoy<sup>&#x000ae; </sup>) in patients with metastatic melanoma (proclivity 02)</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Patel</surname><given-names>Sapna</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Milhem</surname><given-names>Mohammed</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Hallmeyer</surname><given-names>Sigrun</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Daniels</surname><given-names>Gregory</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Cranmer</surname><given-names>Lee</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Taback</surname><given-names>Bret</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Flaherty</surname><given-names>Lawrence</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Aung</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" corresp="yes" id="A9"><name><surname>Lowder</surname><given-names>James</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Sharfman</surname><given-names>William</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib></contrib-group><aff id="I1"><label>1</label>MD Anderson Cancer Center, Houston, TX, USA</aff><aff id="I2"><label>2</label>University of Iowa, Iowa City, IA, USA</aff><aff id="I3"><label>3</label>Oncology Specialists SC, Park Ridge, IL, USA</aff><aff id="I4"><label>4</label>Moores Cancer Center, La Jolla, CA, USA</aff><aff id="I5"><label>5</label>University of Arizona Cancer Center, Tucson, AZ, USA</aff><aff id="I6"><label>6</label>Columbia University, New York, NY, USA</aff><aff id="I7"><label>7</label>Karmanos Cancer Center, Detroit, MI, USA</aff><aff id="I8"><label>8</label>Prometheus Laboratories, San Deigo, CA, USA</aff><aff id="I9"><label>9</label>Johns Hopkins University, Baltimore, MD, USA</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>6</day><month>11</month><year>2014</year></pub-date><volume>2</volume><issue>Suppl 3</issue><supplement><named-content content-type="supplement-title">Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)</named-content></supplement><fpage>P78</fpage><lpage>P78</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Patel et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Patel et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/2/S3/P78"/><conference><conf-date>6-9 November 2014</conf-date><conf-name>Society for Immunotherapy of Cancer 29th Annual Meeting</conf-name></conference></article-meta></front><body><sec><title>Purpose</title><p>To investigate whether the sequence of HD IL-2 and a checkpoint inhibitor, Ipilimumab, will have additive or synergistic efficacy or toxicity when used in rapid sequence.</p></sec><sec><title>Schema</title><p>Adult patients with Stage IV or unresectable Stage III metastatic melanoma who are eligible to receive HD IL-2, treatment na&#x000ef;ve or have received prior adjuvant therapy are randomized to a sequential administration of 4 doses of Ipilimumab or 4 cycles of HD IL-2 dosed according to their package inserts (figure <xref ref-type="fig" rid="F1">1</xref>). Fifty of the patients will start with one drug and 50 the other. The second drug will begin as soon as practically possible, without waiting for relapse. Entry criteria have recently been amended to include prior treatment with anti-PD-1 or anti-PDL-1. Twelve US sites are currently enrolling patients. An independent Data and Safety Monitoring Committee oversees the study. The primary endpoint is the proportional one year survival in the ITT population and a protocol defined population of patients who have received at least half of the planned doses of both study drugs. Clinical response and progression free survival will also be assessed. The primary endpoint is the proportional one year survival in the ITT population and a protocol defined population of patients who have received at least half of the planned doses of both study drugs. Clinical response and progression free survival will also be assessed.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin<sup>&#x000ae; </sup>(HD IL-2) and Ipilimumab Yervoy<sup>&#x000ae;</sup>) in patients with metastatic melanoma (proclivity 02)</p></caption><graphic xlink:href="2051-1426-2-S3-P78-1"/></fig></sec><sec><title>Current status</title><p>Twelve US sites are currently enrolling patients. To date 16 patients have been enrolled, 9 on the Ipilimumab first and 7 on the HD IL-2 first arms. No synergistic toxicity has been observed, but one death occurred in the HD IL-2 arm and one colectomy on the Ipilimumab arm, both prior to administration of the other drug.</p></sec></body></article>